Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Claris Biotherapeutics

Status and phase: Enrolling; Phase 1

Conditions: Limbal Stem Cell Deficiency

Treatments: Biological: CSB-001 Ophthalmic Solution 0.1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT06452316

CSB-C23-001

Details and patient eligibility

About

This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes. The study is comprised of two identical phases (Dosing Phase I and II) of test article dosing separated by a 31- to 40-day period, the Dosing Holiday, where no test article is administered. Dosing Phase II is followed by an observational, noninterventional phase (Observation Phase).

Enrollment: 65 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have an area of the central 5 mm zone of cornea affected, presence of at least one clinical sign observed by slit-lamp examination with white light and/or cobalt blue light, fluorescein, and a Wratten filter, and at least one clinical sign observed with AS-OCT.
• If dosing with Acthar at time of Screening Visit, must have a history of stable dosing for approximately 8 weeks, plan to maintain the same Acthar treatment dose and regimen, and have demonstrated little to no improvement in severity of LSCD.
• Sponsor written confirmation of qualifying LSCD diagnosis.
• Inflammation associated with LSCD or other non-infectious inflammation that will not interfere with subject's participation.

Exclusion criteria

• Any active ocular infection (bacterial, viral, fungal, or protozoan) in either eye.
• Ocular surgery within 30 days of Day 0 where investigator assesses that healing is not considered complete/stable.
• Planned ocular surgery on or before Week 20 visit.
• Presence or history of any ocular or systemic disorder, condition, or procedure that might hinder the efficacy of the study treatment or its evaluation, or could interfere with the interpretation of study results, in the opinion of the investigator.

Note: Other inclusion/exclusion criteria apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

65 participants in 2 patient groups

Control

Experimental group

Description:

Observation (non-interventional) for 20 weeks followed by one drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s) separated by \>30 days and \<40 days followed by observation for 8 weeks (total participation of 48 weeks)

Treatment:

Biological: CSB-001 Ophthalmic Solution 0.1%

CSB-001 QID

Experimental group

Description:

One drop CSB-001 four times daily for two 8-week dosing periods in the study eye(s) separated by \>30 days and \<40 days followed by observation (non-interventional) for 28 weeks (total participation of 48 weeks)

Treatment:

Biological: CSB-001 Ophthalmic Solution 0.1%